HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?

Abstract

Authors

T Maity K Mann P Mott T Quader C Malmberg

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×